Tag: the war on (some) drugs

Carlos Lehder reveals: Fidel and Raúl Castro facilitated Medellín Cartel drug trafficking from Cuba in the 1980s.

Carlos Lehder, co-founder of the Medellín Cartel and former ally of Pablo Escobar, has dropped a bombshell that the left and progressives don’t want to hear: the Cuban regime, led by Fidel and Raúl Castro, was a key ally in trafficking cocaine to the United States in the 1980s.

This truth, revealed exclusively by Martí Noticias, shatters the image of Cuba as a supposed revolutionary model and exposes the corruption and cynicism of a government that conservatives have always denounced.

While progressives in the U.S. and Europe were busy praising Castro, this regime was helping flood the streets with drugs, lining their pockets and betraying their own people.

Lehder is direct in pointing out the culprits. In his memoirs and interviews, he states:

I met with Raúl Castro and Colonel Antonio de la Guardia to negotiate the logistics of these operations.

He details how Cuba opened its doors to the Medellín Cartel, setting up airstrips in Cayo Largo and charging for every kilo of cocaine that passed through the island. And he leaves no doubt about who was in charge:

Fidel Castro had to know; he was the orchestra conductor.

This isn’t gossip; it’s the testimony of a drug trafficker who lived the business from the inside and now exposes the hypocrisy of the Castros.

For Republicans, this comes as no surprise. We’ve always seen the Cuban regime as a nest of opportunists who crush their people while engaging in dirty business. While the left romanticizes Fidel and Raúl, Lehder reveals the reality:

I was allowed to use facilities in Cayo Largo, where airstrips were set up and a payment was agreed upon for each kilo of cocaine transported.

That drug made its way to the streets, killing young people, all under a government that progressives defended as a «victim» of imperialism. What irony.

Keep reading

New York Officials Take Steps To Expand Marijuana Farmers Market Program

New York marijuana regulators are moving forward with new proposed regulations around the state’s so-called “cannabis showcase” program, which allows licensed businesses to sell to consumers at pop-up, farmers market-like events.

Members of the Cannabis Control Board (CCB), which oversees the state’s Office of Cannabis Management (OCM), voted without opposition at a meeting on Tuesday to advance the 23-page showcase expansion plan, which next proceeds to a public comment stage.

The new rules follow the enactment of legislation signed by Gov. Kathy Hochul (D) in March that built on the existing showcase program, which was first created in 2023.

In a presentation to the board on Tuesday, John Kagia, OCM’s director of policy, said the program has “proved to be a particularly compelling way for the new, fast-growing, regulated cannabis market to get out in the community, to build relationships with consumers and to begin the process of normalizing cannabis in the state of New York.”

Between summer 2023 and the end of that year, he noted, New York saw over 60 showcase events that together brought in more than $10 million in revenue for participating businesses.

“It really established that there was real interest, both from the licensees and from the communities where these events were being hosted, to allow cannabis to exist out of the four walls of our retail dispensaries,” Kagia said.

Keep reading

Connecticut House Passes Psilocybin Decriminalization Bill To Remove Threat Of Jail For Possessing The Psychedelic

The Connecticut House of Representatives has approved a bill to decriminalize psilocybin for adults—despite lingering questions about whether the state’s Democratic governor would support it after he rejected an earlier version of the reform measure.

One month after the measure cleared the legislature’s Joint Judiciary Committee, it cleared the full chamber in a 74-65 vote on Monday. It now heads to the Senate for consideration.

If enacted into law, the legislation would make possession of up to one-half an ounce of psilocybin punishable by a $150 fine, without the threat of jail time.

“Psilocybin is a product which has been shown to be an effective therapeutic for various mental illnesses, including treating PTSD, addictions, depressions and anxiety disorders,” Rep. Steve Stafstrom (D), co-chair of the Judiciary Committee, said on the floor. “It is a substance that our state currently treats as the equivalent of cocaine, heroin or any other sort of serious Schedule I drug that, if folks are caught with possession of even a tiny little bit, Mr. Speaker, even even personal use of psilocybin, they’d be essentially subject to a class A misdemeanor and up to a year in jail.”

“What this bill seeks to do is pretty simple. It doesn’t legalize the substance. I want to be really clear: This bill does not legalize psilocybin,” he said. “If you’re dealing psilocybin, if you’re driving under the influence of psilocybin, those penalties remain the same as they are under existing law. Driving under the influence of psilocybin, it’s driving under the influence. No change in this bill. Dealing psilocybin continues to be drug dealer offense. You can be prosecuted for drug dealing—that does not change.”

Keep reading

Montana Governor Signs Bill Directing Marijuana Tax Revenue Toward Environmental Conservation And Wildlife

Montana Gov. Greg Gianforte (R) announced on Friday that he had recently signed House Bill 932, a proposal that would expand uses for the conservation-dedicated tax revenues the state collects on recreational marijuana sales.

Under HB 932, the scope of wildlife habitat protection and improvement supported with marijuana taxes will broaden to include projects implemented on private land. The law is slated to take effect July 1.

Before the latest legislative reform, Habitat Montana was the sole beneficiary of the roughly $10 million of habitat-conservation-dedicated funding that marijuana revenues support. In recent years, Montana Fish, Wildlife and Parks (FWP) has used Habitat Montana to purchase new Wildlife Management Areas and secure both perpetual conservation easements and 40-year conservation leases.

With HB 932 in play this summer, that $10 million of conservation funding will all go into a new account: the “habitat legacy account.”

From there, it will be further divided into three separate funding buckets.

Most of the money, 75 percent, will support Habitat Montana and state water projects. Roughly 20 percent of the remainder will be funneled into an existing program called the Wildlife Habitat Improvement Program, or WHIP, and 5 percent will be directed toward the newly established wildlife crossings account that seeks to reduce the wildlife-vehicle collisions that plague the state’s highways and interstates.

Keep reading

DEA Blames Legal Marijuana States For Inadvertently Aiding Cartels While Also Admitting That Prohibition States Create Illegal Market Opportunities

The Drug Enforcement Administration (DEA) says that states that have legalized marijuana are providing cover for illicit cultivation operations by foreign cartels—while at the same time implicitly acknowledging that ongoing prohibition in other states creates opportunities for that cannabis to be sold on the illegal market.

The agency’s 2025 National Drug Threat Assessment that was released on Thursday includes a section on marijuana trafficking, claiming that cartels and other organized crime groups “operate under business registrations granted by state licensing authorities in jurisdictions where marijuana cultivation and sales are ‘legal’ at the state level.”

“However, absent overt evidence such as the trafficking of marijuana across state lines or the commission of non-drug crimes such as money laundering and human trafficking, it can be difficult for law enforcement to immediately identify violations or discover an illegal grow,” the report says. “Asian [Transnational Criminal Organizations, or TSOs] defy restrictions on plant quantities, production quotas, and non-licensed sales, and hide behind state-by-state variations in laws governing plant counts, registration requirements, and accountability practices.”

DEA suggested that cartels are leveraging state cannabis markets by transporting “large amounts of marijuana directly from ‘legal’ states to states that have not legalized recreational use and those where state-level recreational approval is sufficiently recent to not yet have an established, regulated cannabis industry.”

Underlying that analysis seems to be a perhaps inadvertent acknowledgment by DEA that cartels are profiting off ongoing prohibition outside of legal states—indicating that the main demand for illicit marijuana isn’t coming from within states that provide regulated access to consumers but instead those where cannabis remains criminalized.

Implicit in that analysis is exactly what advocates have long argued: Legalization disrupts the illegal market.

Keep reading

Members Of Congress Want Federal Investigation Into Use Of Florida Medicaid Funds To Oppose Marijuana Legalization By Group Tied To DeSantis

Two Democratic members of Congress representing Florida are asking the federal government to investigate what they describe as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to Gov. Ron DeSantis (R). The money was used to fight against a citizen ballot initiative, vehemently opposed by DeSantis, that would have legalized marijuana for adults.

Reps. Kathy Castor and Darren Soto sent a letter on Thursday to the Department of Health and Human Services (HHS) inspector general as well as Mehmet Oz, the administrator of the Centers for Medicare and Medicaid Services, formally requesting they initiate a Medicaid fraud investigation.

“The diversion of Medicaid dollars requires immediate investigation,” the two lawmakers wrote. “These are proceeds that rightfully belong to state taxpayers to serve the citizens who rely on Medicaid, including children, pregnant women, neighbors with disabilities and those served by long-term care.”

The two lawmakers, members of a House committee with oversight of Medicaid, emphasized that Congress is “very focused on waste, fraud and abuse of Medicaid dollars.”

“Any unlawful diversion of Medicaid dollars in Florida,” they wrote, “means that the state is less able to provide services to our neighbors who rely on Medicaid and the providers who serve them.”

The letter follows allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing the proposed marijuana legalization ballot measure, Amendment 3.

Notably, the Hope Florida Foundation was founded by Florida First Lady Casey DeSantis, the governor’s wife.

“On October 17, Secure Florida’s Future donated $2 million to Keep Florida Clean Inc., a Political Action Committee (PAC) controlled by Governor DeSantis’s then-chief of staff James Uthmeier that was created to campaign against Amendment 3,” the lawmakers’ new letter says. “Governor DeSantis strongly opposed Amendment 3. Days later, Secure Florida’s Future sent Keep Florida Clean Inc. an additional $1.75 million.”

“On October 22, the Hope Florida Foundation wired $5 million to the 501(c)4 nonprofit Save Our Society from Drugs that proposed spending the ‘grant’ on ‘developing and implementing strategies that directly address the substance use crisis facing our communities,’” it continues, detailing the alleged impropriety. “On October 23, the next day, Save Our Society from Drugs donated $1.6 million to Keep Florida Clean Inc. Over the coming days, Save Our Society from Drugs donated an additional $3.15 million to Keep Florida Clean Inc.”

“While there are limited financial disclosure requirements associated with 501(c)4 organizations,” the lawmakers said, “records appear to show that a total of $8.5 million from the Centene settlement with AHCA went from the Hope Florida Foundation to the Amendment 3-focused Keep Florida Clean, Inc. PAC, the same PAC that also donated funding to the Republican Party of Florida and the Florida Freedom Fund. ”

“Hope Florida had raised only about $2 million during its three years of existence,” they pointed out, “but in one fell swoop, received $10 million from a Medicaid settlement, which was immediately funneled through other nonprofits to a PAC directed by the Governor’s Chief of Staff.”

Keep reading

Psilocybin use has surged in the United States since 2019

The use of psilocybin—the active compound in so-called “magic mushrooms”—has increased significantly in the United States since 2019, according to a new study published in the Annals of Internal Medicine. Drawing on data from five national sources, researchers found sharp increases in both lifetime and recent use, especially among adults with symptoms of anxiety, depression, and chronic pain.

Psilocybin is a naturally occurring hallucinogen found in certain species of mushrooms. It has attracted growing scientific and public attention due to promising early studies suggesting it may help treat depression, post-traumatic stress disorder, and substance use disorders. Although not currently approved by the U.S. Food and Drug Administration, psilocybin has entered clinical trials and has been decriminalized or legalized in parts of Oregon, Colorado, and several municipalities. This shifting legal landscape has raised questions about whether broader public use is increasing—and what the public health consequences might be.

“With efforts to legalize psilocybin mushrooms in Colorado, Oregon, and elsewhere ongoing, we wanted to determine whether there were more people using psilocybin mushrooms now than when legalization first passed here in Denver in 2019,” said Joshua Black, the co-lead author and senior scientist at Rocky Mountain Poison and Drug Safety, a division of Denver Health.

To investigate these trends, the researchers analyzed five major U.S. data sources to examine psilocybin use from 2014 to 2023: the National Survey on Drug Use and Health, the Survey of Non-Medical Use of Prescription Drugs, Monitoring the Future, the National Poison Data System, and the National Hospital Ambulatory Medical Care Survey. By comparing responses across these sources, the team aimed to track changes in who is using psilocybin, how often, and whether they’re showing up in healthcare settings as a result.

The researchers chose 2019 as a key benchmark, since that year marked the first legal policy changes regarding psilocybin in the United States. Until then, use patterns were relatively stable. But after 2019, things began to shift. According to the National Survey on Drug Use and Health, lifetime use of psilocybin among adults rose from 10 percent (around 25 million people) in 2019 to 12.1 percent (over 31 million people) in 2023. Among adolescents aged 12 to 17, lifetime use rose more modestly, from 1.1 percent to 1.3 percent.

The increases were even more dramatic when looking at recent use. Among adults aged 18 to 29, past-year use rose 44 percent from 2019 to 2023. Among adults 30 and older, it jumped 188 percent. By 2023, 2.1 percent of adults reported using psilocybin in the past year—more than the number who reported using cocaine, LSD, methamphetamine, or illegal opioids.

Keep reading

Alabama Governor Faces Contrasting Calls To Sign Or Veto Hemp Regulation Bill On Her Desk

A bill aimed at regulating consumable hemp products has landed on Gov. Kay Ivey’s (R) desk, but its future is uncertain.

HB 445, sponsored by Rep. Andy Whitt (R-Harvest), would establish regulations for consumable hemp products in Alabama, but the bill’s language and potential consequences have led the hemp industry to suggest the possibility of litigation and led to uncertainty among lawmakers, business owners, patients and lobbyists.

“It is my hope that the governor signs the bill this week. I think it’s a good piece of legislation. I think it’s a bipartisan piece of legislation, and certainly, we have to get the guardrails up on this industry,” Whitt said in a phone interview Tuesday.

Key provisions of the bill include:

  • Testing and labeling requirements for all consumable hemp products.
  • Caps of 10 milligrams per individually wrapped product, with a cap of 40 milligrams per package.
  • Authorization for the Alcoholic Beverage Control (ABC) Board to license retailers of these products.
  • Restrictions on retail establishments selling hemp products.
  • Prohibition of sales to minors.
  • Prohibition of smokable hemp products and restrictions on online sales and direct delivery.
  • Imposition of an excise tax on consumable hemp products.

The bill defines “consumable hemp product” broadly as any finished product intended for human or animal consumption that contains any part of the hemp plant or its derivatives, but explicitly bans smokable hemp products and certain psychoactive cannabinoids.

Keep reading

Trump’s DEA Pick Refuses To Detail Marijuana Rescheduling Stance In Response To Senator’s Questions

In written responses to questions from two Democratic senators as part of his confirmation, the nominee for DEA administrator, Terrance Cole, largely demurred on multiple questions around marijuana policy issues, including a pending proposal to move cannabis from Schedule I to Schedule III that was initiated under the Biden administration.

Asked by Sens. Cory Booker (D-NJ) and Alex Padilla (D-CA) about his position on that proposal, Cole—who has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth—simply said that, if confirmed, he will “give the matter careful consideration after consulting with appropriate personnel within the Drug Enforcement Administration, familiarizing myself with the current status of the regulatory process, and reviewing all relevant information.”

While he gave noncommittal answers when asked about rescheduling in the written questions, Cole said during an in-person hearing before the Senate Judiciary Committee last month that examining the rescheduling proposal will be “one of my first priorities” if he’s confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see.

“I’m not familiar exactly where we are, but I know the process has been delayed numerous times—and it’s time to move forward,” he told Padilla at the time. “I need to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process.”

In the newly released written questions, Booker further asked the nominee whether he felt DEA is “bound” by the scheduling process as articulated under the Controlled Substances Act (CSA).

“As in all matters, if confirmed, I would look at the individualized facts and circumstances and follow the law and any policies of the Department,” Cole said.

Keep reading

Sinaloa cartel leaders charged with narco-terrorism after authorities seize nearly 2 tons of fentanyl

Two leaders of the Sinaloa Cartel were hit with narco-terrorism charges on Tuesday for their involvement in allegedly trafficking “massive” amounts of drugs into the United States, according to federal officials.

Pedro Inzunza Noriega and his son, Pedro Inzunza Coronel, were both named in an unsealed federal indictment on Tuesday and charged with narco-terrorism, material support of terrorism, drug trafficking and money laundering as members of the Beltran Leyva Organization (BLO), which is a faction of the Sinaloa Cartel.

Five other BLO leaders were charged with drug trafficking and money laundering.

The charges come after the Trump administration designated the Sinaloa Cartel as a Foreign Terrorist Organization on Feb. 20.

Prosecutors alleged in court documents that Noriega works closely with his son to both produce and “aggressively traffic” fentanyl into the United States.

Keep reading